Kevin Killeen is the Chief Scientific Officer at Matrivax Research & Development Corp. He has extensive training in the fields of molecular biology, microbiology, protein chemistry, immunology, and vaccinology. His BS degree is from Stonehill College (biology and chemistry), PhD from University of Rhode Island (microbiology), and post-doctoral fellowship at Harvard Medical School (molecular genetics and protein toxin chemistry). He has 30 years of experience in the field of biotechnology at IDEXX Corp., AVANT-Celldex Inc, and Matrivax Corp. He has published over 30 vaccine related manuscripts, authored four chapters, is an inventor on nine patent/applications, and 10-year member of the Dean’s Advisory Council at URI. He was the principal investigator on vaccine related grants and contracts exceeding $11 MM from the Bill & Melinda Gates Foundation.
Kevin’s career highlights include the commercialization of two diagnostic tests, directing 7 vaccine candidates into Phase 1 and 2 clinical trials, and guiding the R&D of CholeraGarde®, an oral, single-dose cholera vaccine towards a Phase 3 clinical trial and out- licensing. He identified and performed scientific due diligence on rotavirus vaccine candidate 89-12, which was out licensed to GSK and commercialized as Rotarix®.